.png){kind=icon}
Return
The Leprosy
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-024-00575-1.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Leprosy, a neglected tropical disease, causes significant morbidity in marginalized communities. Before the COVID-19 pandemic, annual new case detection plateaued for over a decade at similar to 200,000 new cases. The clinical phenotypes of leprosy strongly parallel host immunity to its causative agents Mycobacterium leprae and Mycobacterium lepromatosis. The resulting spectrum spans from paucibacillary leprosy, characterized by vigorous pro-inflammatory immunity with few bacteria, to multibacillary leprosy, harbouring large numbers of bacteria with high levels of seemingly non-protective, anti-M. leprae antibodies. Leprosy diagnosis remains clinical, leaving asymptomatic individuals with infection undetected. Antimicrobial treatment is effective with recommended multidrug therapy for 6 months for paucibacillary leprosy and 12 months for multibacillary leprosy. The incubation period ranges from 2 to 6 years, although longer periods have been described. Given this lengthy incubation period and dwindling clinical expertise, there is an urgent need to create innovative, low-complexity diagnostic tools for detection of M. leprae infection. Such advancements are vital for enabling swift therapeutic and preventive interventions, ultimately transforming patient outcomes. National health-care programmes should prioritize early case detection and consider post-exposure prophylaxis for individuals in close contact with affected persons. These measures will help interrupt transmission, prevent disease progression, and mitigate the risk of nerve damage and disabilities to achieve the WHO goal 'Towards Zero Leprosy' and reduce the burden of leprosy.
Keywords:
SINGLE-DOSE RIFAMPICIN
DAPSONE HYPERSENSITIVITY SYNDROME
MULTIBACILLARY MB LEPROSY
MULTIDRUG THERAPY REGIMEN
INTERNATIONAL OPEN TRIAL
NEWLY-DIAGNOSED LEPROSY
MYCOBACTERIUM-LEPRAE
POSTEXPOSURE PROPHYLAXIS
PHENOLIC GLYCOLIPID-1
LEPROMATOUS LEPROSY
Journal
N
IF:
60.6
Papers:
649
Citations:
3.8W
Organization
Cited Papers
ShareSaveShareSaveAccuracy and Tuning of Flow Parsing for Visual Perception of Object Motion During Self-Motion.png)
i-Perception
OAAI
i-PerceptionIF0
OAAIShareSaveShareSaveDC-SIGN association with the Th2 environment of lepromatous lesions: cause or effect?JOURNAL OF PATHOLOGY
JOURNAL OF PATHOLOGYIF5.2
PREAI
ShareSavePopulation Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the ComorosOAAI
OAAIShareSave
View more